Variables predictivas de respuesta a la eritropoyetina recombinante humana en pacientes con anemia y cáncer. / [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer]
Medicina [B Aires]
; 62(1): 41-7, 2002.
Article
in Spanish
| BINACIS
| ID: bin-39257
Responsible library:
AR2.1
ABSTRACT
The use of human recombinant erythropoietin (rHuEpo) has been approved by the Food and Drug Administration (FDA) in patients with anemia and cancer. Although good results have been obtained, it is too expensive to permit its use massively. For the purpose of evaluating the therapeutic effect of rHuEpo, including toxicity, predictive response variables and quality of life parameters, a prospective trial was carried out in patients with anemia and cancer. Hematimetric parameters, ferritin, Epo, cytokines, transfusions and quality of life were registered. A total of 36 patients were treated in the protocol (34 were evaluable) 16 men and 20 women, with a medium age 56.4 years; 27 patients were treated with chemotherapy (16 with cisplatinum); 15 patients presented medullar infiltration. In 73.5
Search on Google
Collection:
National databases
/
Argentina
Database:
BINACIS
Type of study:
Practice guideline
/
Prognostic study
/
Risk factors
Aspects:
Patient-preference
Language:
Spanish
Journal:
Medicina [B Aires]
Year:
2002
Document type:
Article